Filtered By:
Specialty: International Medicine & Public Health
Condition: Bleeding
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 274 results found since Jan 2013.
Apixaban lowers stroke risk in AF patients undergoing cardioversion (EMANATE)
(European Society of Cardiology) Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-na ï ve patients with atrial fibrillation scheduled for elective cardioversion, according to late-breaking results from the EMANATE trial presented today in a Hot Line LBCT Session at ESC Congress. Rates of bleeding were similar between the two groups.
Source: EurekAlert! - Medicine and Health - August 28, 2017 Category: International Medicine & Public Health Source Type: news
Compliance with accreditation and recommended hospital care —a Danish nationwide population-based study
ConclusionHigh compliance with accreditation standards was associated with a higher level of evidence-based hospital care in Danish hospitals.
Source: International Journal for Quality in Health Care - August 22, 2017 Category: International Medicine & Public Health Source Type: research
Copaiba: Silver bullet or snake oil?
(Florida Atlantic University) Sales of the essential oil copaiba are increasing, at least in part, because more than 54 million Americans suffer from some form of arthritis. The conventional way to treat arthritis is using NSAIDs as well as cyclo-oxygenase-2 inhibitors (COXIBs), which are not without adverse events like gastrointestinal bleeding, heart attacks and stroke. For arthritis sufferers, copaiba may turn out to be a silver bullet or, perhaps, snake oil.
Source: EurekAlert! - Medicine and Health - June 6, 2017 Category: International Medicine & Public Health Source Type: news
Combining risk scores improves decision-making process for AFib patients and physicians
(Intermountain Medical Center) By combining a patient's traditional risk score with the Intermountain Mortality Risk Score, physicians and patients are better equipped to evaluate a patient's individual risk of stroke, bleeding, and mortality with atrial fibrillation, according to a new study of more than 80,000 patients from the Intermountain Medical Center Heart Institute in Salt Lake City.
Source: EurekAlert! - Medicine and Health - May 11, 2017 Category: International Medicine & Public Health Source Type: news
Intra-hospital correlations among 30-day mortality rates in 18 different clinical and surgical settings
Conclusions</div>The variability in 30-day mortality rates at hospital level and the correlation between risk mortality rates suggest that there may be common hospital-wide factors influencing short-term mortality.</span>
Source: International Journal for Quality in Health Care - January 31, 2017 Category: Global & Universal Source Type: research
Dabigatran superior to warfarin when anticoagulation is resumed after bleeding
(University of Pittsburgh Schools of the Health Sciences) In the first analysis of how to treat patients on anticoagulants who suffer a major bleeding event, a clinical practice that routinely gives doctors pause, while also evaluating a new drug, University of Pittsburgh researchers aim to provide much-needed guidance to clinicians trying to balance the risks of stroke versus bleeding when determining the best treatment.
Source: EurekAlert! - Social and Behavioral Science - December 1, 2016 Category: Global & Universal Source Type: news
New oral anticoagulants provide same stroke prevention as warfarin but cause less bleeding
(European Society of Cardiology) The new oral anticoagulants provide the same stroke prevention as warfarin but cause less intracranial bleeding, reports an observational study in more than 43,000 patients presented at ESC Congress 2016 today by Dr. Laila Staerk, a research fellow at Herlev and Gentofte University Hospital, Denmark.
Source: EurekAlert! - Medicine and Health - August 27, 2016 Category: Global & Universal Source Type: news
Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review
Conclusion Stroke risk reduction and a moderate increase in the risk of bleeding are the most important attributes for an AF patient when deciding whether they are for or against OAC treatment. If different anticoagulation options have similar clinical characteristics, convenience attributes matter to patients. In this review, AF patients favour attribute levels that describe NOAC treatment.
Source: The Patient - Patient-Centered Outcomes Research - July 25, 2016 Category: Global & Universal Source Type: research
New imaging method may predict risk of post-treatment brain bleeding after stroke
(NIH/National Institute of Neurological Disorders and Stroke) In a study of stroke patients, investigators confirmed through MRI brain scans that there was an association between the extent of disruption to the brain's protective blood-brain barrier and the severity of bleeding following invasive stroke therapy. The results of the National Institutes of Health-funded study were published in Neurology.
Source: EurekAlert! - Medicine and Health - June 17, 2016 Category: Global & Universal Source Type: news
Standard blood pressure target is sufficient for treating some strokes
(NIH/National Institute of Neurological Disorders and Stroke) An international stroke study found that standard and intensive blood pressure treatments were equally effective in the emergency treatment of acute intracerebral hemorrhage, a type of stroke caused by bleeding into the brain. The study, published in the New England Journal of Medicine, was funded by the NIH's National Institute of Neurological Disorders and Stroke.
Source: EurekAlert! - Medicine and Health - June 8, 2016 Category: Global & Universal Source Type: news
PS084 Stroke Due Discontinuance Irregular of Aspirin in Cirurgies Noncardiacs
Acetylsalicylic acid (ASA) is related to higher rate of postoperative bleeding, however, its discontinuity implies increasing cardiovascular disease and increased perioperative mortality.
Source: CVD Prevention and Control - May 31, 2016 Category: Global & Universal Authors: J.A.D. Silveira, F.J. Matheus, A. Meneghini, A.L. Queiroz, C.J. Arroyo Neto, A.C.P. Chagas Tags: Poster Abstract Source Type: research
PM176 Effect of Mitral Regurgitation in Non-Rheumatic Atrial Fibrillation Patients Taking and not Taking Warfarin on Stroke and Bleeding
Atrial fibrillation (AF) increases risk of stroke significantly. Prevention of this complication by using anticoagulant is recommended when the benefits outweigh the risks. Many AF patients also have mitral regurgitation (MR) as co-morbidity. However, there is lack of data describing the relationship between the bleeding risk and expected benefit from using anticoagulant in this kind of patients.
Source: CVD Prevention and Control - May 31, 2016 Category: Global & Universal Authors: Y. Vorasettakarnkij, K. Chintanavilas Tags: Poster Abstract Source Type: research
Attitudes toward anticoagulant treatment among nonvalvular atrial fibrillation patients at high risk of stroke and low risk of bleed
Conclusion: Results suggest that many AF patients who are at high risk of stroke but at low risk of bleed may not be receiving AC due to potentially inaccurate beliefs about risk. This study also found that AF patients place trust in physicians above other factors such as cost when making treatment decisions. Increased education of patients by physicians on the risks and benefits may be a simple strategy to improve outcomes. Keywords: atrial fibrillation, anticoagulants, stroke risk, bleeding risk, treatment
Source: Patient Preference and Adherence - May 16, 2016 Category: Global & Universal Tags: Patient Preference and Adherence Source Type: research
Cost Effectiveness of Apixaban (Novel Oral Anti-Coagulant) Compared with Conventional Therapy for Stroke Prophylaxis among Renal Impaired Patients with Atrial-Fibrillation from Perspective of Us Third Party Payer
Atrial Fibrillation (AF) has been a major risk factor for the development of stroke making anticoagulation therapy necessary. While on prophylaxis treatment, renal impaired patients on conventional anticoagulation (Warfarin) are at an increased risk for major bleeding. Apixaban has been shown to have better safety profile than Warfarin in face to face clinical trial. However, no study were found to have compared the cost effectiveness of Apixaban with Warfarin among renal impaired patients. We attempted to estimate the short term (one year) cost effectiveness of Apixaban compared to Warfarin for stroke prophylaxis among re...
Source: Value in Health - April 30, 2016 Category: Global & Universal Authors: A Kumar, W Wu, M Nili Source Type: research
